Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
bimekizumab
Pharma Mar S.A.
Hidradenitis Suppurativa
1 trial -
bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).
Pharma Mar S.A.
Psoriatic arthritis
1 trial -
brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance
Pharma Mar S.A.
Childhood Absence Epilepsy Juvenile Absence Epilepsy
1 trial -
brivaracetam, brivaracetam, brivaracetam, brivaracetam
Pharma Mar S.A.
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
1 trial -
sotatercept, PL1 - Powder for injection
Pharma Mar S.A.
Therapeutic confirmatory (phase III)
1 trial -
sotatercept, sotatercept
Pharma Mar S.A.
Pulmonary Arterial Hypertension (PAH)
1 trial -
(+)-α-DIHYDROTETRABENAZINE
Pharma Mar S.A.
Tardive dyskinesia
1 trial -
(+)-α-DIHYDROTETRABENAZINE
Pharma Mar S.A.
tardive dyskinesia
1 trial -
(+)-α-DIHYDROTETRABENAZINE, ADE513 placebo
Pharma Mar S.A.
Tardive dyskinesia
1 trial -
-
Pharma Mar S.A.
Myocardial Infarction, Acute Heart Failure, Left Sided
1 trial -
-, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -
Pharma Mar S.A.
Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies
1 trial -
-, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -
Pharma Mar S.A.
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
0.9% Sodium Chloride for Injection (Fresenius Kab) sourced locally by sites, AP-101
Pharma Mar S.A.
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
Pharma Mar S.A.
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults
1 trial -
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis
Pharma Mar S.A.
Primary Hyperoxaluria
1 trial -
A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.
Pharma Mar S.A.
Glioblastoma
1 trial -
ABO-102, ABO-102, ABO-102
Pharma Mar S.A.
Mucopolysaccharidosis type IIIA
1 trial -
AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALEN®
Pharma Mar S.A.
Idiopathic Sudden Sensorineural Hearing Loss
1 trial -
ACT-1004-1239 matching placebo
Pharma Mar S.A.
Progressive multiple sclerosis (MS)
1 trial -
ADX-038
Pharma Mar S.A.
Complement-Mediated Kidney Disease
1 trial -
ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale
Pharma Mar S.A.
Geographic atrophy secondary to age-related macular degeneration
1 trial -
AL8326
Pharma Mar S.A.
- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.
1 trial -
AL8326
Pharma Mar S.A.
Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.
1 trial -
ALDARA 5% cream, Keramod® gel
Pharma Mar S.A.
Actinic keratosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources